Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Werewolf Therapeutics (NASDAQ:HOWL) in the latest quarter, with a majority being bullish. The average 12-month price target is $13.8, which is 8.0% lower than the previous average. The company faces financial challenges, including a significant revenue decline, but maintains strong net margins, ROE, and ROA compared to industry benchmarks.
May 24, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Werewolf Therapeutics (NASDAQ:HOWL) received mixed analyst ratings, with a majority being bullish. The average 12-month price target is $13.8, down 8% from the previous average. The company faces significant revenue decline but maintains strong net margins, ROE, and ROA.
The mixed analyst ratings and the downward revision of the average price target suggest a neutral short-term impact on the stock price. While the company faces financial challenges, its strong net margins, ROE, and ROA provide some positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100